We are live on ! Find out more
BSX icon

Boston Scientific

43.89 USD
-0.43
0.97%
At close Updated Nov 3, 1:27 PM EST
1 day
-0.97%
5 days
4.62%
1 month
3.51%
3 months
-9.37%
6 months
-22.8%
Year to date
-53.66%
1 year
-55.48%
5 years
2.28%
10 years
103.76%
 

About: Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

Employees: 59,000

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 28.9%
Neutral 26.5%
Negative 44.6%
Positive
Zacks Investment Research
3 hours ago
Is BSX Worth Buying Now as Low Valuation Meets Weak Earnings Growth?
Boston Scientific's steep valuation discount faces a major test as earnings estimates weaken, core franchises lose momentum and key growth catalysts shift to 2028.
Is BSX Worth Buying Now as Low Valuation Meets Weak Earnings Growth?
Neutral
Business Wire
19 hours ago
Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences (“BXLS”) today announced a $455 million collaboration with Boston Scientific Corporation (NYSE: BSX) to co-fund the development of the VITALYST™ Temporary Percutaneous Transvalvular Circulatory Support System program. The VITALYST system is a next-generation, miniature heart pump intended to increase cardiac output and improve blood flow from the heart to the brain and other vital organs. It is designed to treat acute myocardial infarc.
Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
Neutral
PRNewsWire
23 hours ago
SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
Both post-implant monotherapies in the trial achieved non-inferiority compared to dual anti-platelet therapy (DAPT) supporting the potential to simplify post-procedure drug regimens MARLBOROUGH, Mass. and SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive six-month primary endpoint results from the SIMPLAAFY randomized controlled trial of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device.
SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
Positive
Zacks Investment Research
3 days ago
Intuitive Surgical vs. Boston Scientific: Which Stock Is a Better Buy Now?
Intuitive Surgical's surging robotic surgery demand and stronger earnings momentum make it a better buy than Boston Scientific despite its valuation premium.
Intuitive Surgical vs. Boston Scientific: Which Stock Is a Better Buy Now?
Negative
24/7 Wall Street
4 days ago
Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.
Pre-Market Stock Futures: Futures are trading lower this Friday, with the Nasdaq down almost 2.
Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.
Negative
Zacks Investment Research
4 days ago
New Strong Sell Stocks for October 30th
BSX, NBHC and NMRK have been added to the Zacks Rank #5 (Strong Sell) List on October 30th, 2026.
New Strong Sell Stocks for October 30th
Neutral
PRNewsWire
4 days ago
Penumbra, Inc. Reports Third Quarter 2026 Financial Results
ALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026.
Penumbra, Inc. Reports Third Quarter 2026 Financial Results
Negative
Zacks Investment Research
5 days ago
BSX Q3 Earnings Call Flags Growth Challenges Through 2027
Boston Scientific faces a challenging 2027 as cybersecurity disruptions, EP and WATCHMAN weakness and China pricing pressures weigh on growth prospects.
BSX Q3 Earnings Call Flags Growth Challenges Through 2027
Negative
Benzinga
5 days ago
These Analysts Revise Their Forecasts On Boston Scientific After Q3 Results
Boston Scientific Corp (NYSE:BSX) on Wednesday posted upbeat third-quarter financial results and cut its FY26 guidance below estimates.
These Analysts Revise Their Forecasts On Boston Scientific After Q3 Results
Negative
MarketBeat
5 days ago
Boston Scientific Q3 Earnings Call Highlights
Boston Scientific NYSE: BSX reported third-quarter 2026 results that fell below its prior guidance after a cybersecurity incident disrupted manufacturing and product shipments for eight business days, while competitive and pricing pressures weighed on key cardiovascular franchises.
Boston Scientific Q3 Earnings Call Highlights
Price charts implemented using Lightweight Charts™